FDA labels checked Oct 2026
Wegovy for Teens: Which GLP-1 Drugs Are Approved Under 18
Two GLP-1 drugs are FDA-approved for weight management from age 12: Wegovy injection (since Dec 23, 2022) and Saxenda (since Dec 4, 2020). Zepbound, Foundayo and the Wegovy pill are approved for adults only.
- Wegovy pen: 12+
- Saxenda: 12+
- Zepbound: not approved under 18
- Foundayo: not approved under 18
We may earn a commission when you click links to providers, and partner relationships can affect which providers we feature and their order. Advertiser Disclosure
01 FDA status
GLP-1 Approval Status for Teens, Drug by Drug
| Drug | Under 18 | Details |
|---|---|---|
| Wegovy injection | Approved 12+ | Weight management with obesity (BMI at or above the 95th percentile). Since Dec 23, 2022. |
| Saxenda (liraglutide 3 mg) | Approved 12+ | Obesity and body weight over 60 kg (132 lb). Since Dec 4, 2020. Brand ends late Jan 2027. |
| Zepbound | Adults only | Label: safety and effectiveness not established in pediatric patients. Teen trials under way. |
| Foundayo | Adults only | Pediatric studies deferred by the FDA; a 12 to 17 trial is ongoing. |
| Wegovy pill, Wegovy HD | Adults only | The tablet and the 7.2 mg dose are approved for adults. |
| Mounjaro, Victoza, Trulicity | Diabetes only, 10+ | Approved for type 2 diabetes from age 10, not for weight loss. |
Sources: section 1 and 8.4 of each label; Foundayo approval letter; Drugs@FDA dates. Using Zepbound or Foundayo under 18 would be off-label. The non-GLP-1 pill Qsymia is also approved from age 12 (June 27, 2022).
02 Wegovy
Wegovy for Teens: Who Qualifies and the Dose
The label covers "pediatric patients aged 12 years and older with obesity." For children, obesity means a BMI at or above the 95th percentile for age and sex on the CDC growth charts, not the adult cutoff of 30. There is no "overweight plus a condition" route for teens.
ages 12 to 17
same 16-week climb as adults
or 1.7 mg if not tolerated
adults only
In STEP TEENS, 87% of teens who finished were on 2.4 mg at the end, and 10% in each group stopped the study drug. Side effects were mostly stomach-related, as in adults. The label's warnings and the thyroid C-cell boxed warning apply at every age. Dosing table: Wegovy dosage; side effects: Wegovy side effects.
03 Saxenda
Saxenda for Teens and Why It Is Ending
Saxenda (liraglutide 3 mg, a daily shot) is approved from age 12 for teens with obesity who weigh more than 60 kg. In its 56-week teen trial of 251 patients, BMI fell 4.3% versus a 0.4% rise on placebo, and 43% versus 19% cut BMI by at least 5%. That is a smaller effect than Wegovy's, from a separate trial.
Ending Novo Nordisk is discontinuing Saxenda, with last shipments to wholesalers in late January 2027. Generic liraglutide 3 mg exists, but some versions are also listed as to be discontinued; ask the pharmacist which label the product carries. Details: Saxenda price and discontinuation.
04 Zepbound and Foundayo
Zepbound and Foundayo for Teens: Not Yet
Not FDA-approved for this use
Zepbound (tirzepatide)
The August 2026 label says safety and effectiveness "have not been established in pediatric patients." Lilly's SURMOUNT-ADOLESCENTS trials are testing it in ages 12 to 17; no teen weight indication exists yet. Mounjaro, the same molecule, was approved for type 2 diabetes from age 10 on Dec 19, 2025.
Not FDA-approved for this use
Foundayo (orforglipron)
Approved April 1, 2026 for adults. The FDA's approval letter defers pediatric studies: a 72-week trial in ages 12 to 17 (ATTAIN-ADOLESCENTS) is ongoing, with completion due March 2028, and an 84-week trial in ages 6 to 11 is planned.
05 Guidelines
What Pediatricians Recommend
The American Academy of Pediatrics' 2023 clinical practice guideline says pediatricians should offer adolescents 12 and older with obesity weight-loss medication, as an addition to health behavior and lifestyle treatment, after weighing benefits and risks with the family. Questions families usually raise with the doctor:
- 1
How long? Weight tends to return after stopping; treatment is planned as long term.
- 2
Eating and growth. Appetite drops a lot, so meals still need enough protein and calories for growth. Raise any history of disordered eating first.
- 3
Who prescribes. Usually a pediatrician or a pediatric weight clinic. Many online GLP-1 programs enroll adults only, so check age rules before signing up.
06 Coverage and cost
Insurance and Cost of Wegovy for Teens
Coverage follows the plan's weight-loss benefit. If the employer plan excludes weight-loss drugs, the exclusion usually applies to dependents too. Where it is covered, expect prior authorization with BMI percentile and growth chart notes. Medicaid rules differ by state: see does Medicaid cover weight loss shots. Plan pages: UnitedHealthcare, Aetna, Blue Cross.
$199 first 2 fills
per 4-pen box
5 pens, about a month
Sources: NovoCare (Oct 16, 2026), Costco (Oct 17, 2026). NovoCare does not say whether self-pay or the savings card applies to patients under 18; ask NovoCare before you fill. More: Wegovy cost.
For parents 18 and older looking at their own options: PlushCare is insurance-based primary care by video, $19.99 a month membership, $129 a visit without insurance (Oct 2026).
Adults: talk to a PlushCare doctor07 FAQ
GLP-1 for Teens FAQ
Can teenagers take Wegovy?
Is Zepbound approved for teens?
How much weight do teens lose on Wegovy?
Is Foundayo approved for teenagers?
What do pediatricians recommend?
Does insurance cover Wegovy for teens?
Related: what GLP-1 is used for · FDA approvals timeline · BMI calculator.
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or qualified health provider with any questions about a medical condition or medication. Never disregard professional medical advice or delay seeking it because of something you have read on this website.
Last updated Oct 23, 2026 · indications and trial data from FDA labels · AAP 2023 guideline · prices from NovoCare and Costco, Oct 2026.
References
- Wegovy (semaglutide) Prescribing Information, revised 06/2026, sections 1, 2.2, 14.3 (Table 18), checked 2026-10-23, Novo Nordisk / FDA, 2026
- Saxenda (liraglutide) Prescribing Information, revised 02/2026, sections 1, 2.2, 14.2 (Table 8), checked 2026-10-23, Novo Nordisk / FDA, 2026
- Zepbound (tirzepatide) Prescribing Information, revised 08/2026, section 8.4, checked 2026-10-23, Eli Lilly / FDA, 2026
- Foundayo (orforglipron) NDA 220934 approval letter, Apr 1, 2026 (deferred pediatric studies), U.S. Food and Drug Administration, 2026
- Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS). N Engl J Med 2022;387:2245-2257, New England Journal of Medicine, 2022
- Kelly AS et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med 2020;382:2117-2128, New England Journal of Medicine, 2020
- Hampl SE et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics 2023;151(2):e2022060640, American Academy of Pediatrics, 2023
- A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2), NCT06439277, ClinicalTrials.gov, 2026
- Wegovy self-pay, checked 2026-10-16, NovoCare, 2026